219 related articles for article (PubMed ID: 30255380)
1. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
Altwerger G; Florsheim EB; Menderes G; Black J; Schwab C; Gressel GM; Nelson WK; Carusillo N; Passante T; Huang G; Litkouhi B; Azodi M; Silasi DA; Santin A; Schwartz PE; Ratner ES
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2449-2456. PubMed ID: 30255380
[TBL] [Abstract][Full Text] [Related]
2. Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin.
Narui C; Tanabe H; Shapiro JS; Nagayoshi Y; Maruta T; Inoue M; Hirata Y; Komazaki H; Takano H; Niimi S; Isonishi S; Okamoto A
In Vivo; 2019; 33(6):2045-2050. PubMed ID: 31662536
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for and prognosis of carboplatin-related hypersensitivity in patients with epithelial ovarian cancer.
Hwang WY; Lee M; Suh DH; Kim K; No JH; Kim YB; Kim JH
Arch Gynecol Obstet; 2022 Aug; 306(2):443-449. PubMed ID: 35044514
[TBL] [Abstract][Full Text] [Related]
4. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.
Takase N; Matsumoto K; Onoe T; Kitao A; Tanioka M; Kikukawa Y; Yamaguchi S; Fujiwara K; Negoro S
Int J Clin Oncol; 2015 Jun; 20(3):566-73. PubMed ID: 25030546
[TBL] [Abstract][Full Text] [Related]
5. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
[TBL] [Abstract][Full Text] [Related]
6. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
7. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation.
Galvão VR; Phillips E; Giavina-Bianchi P; Castells MC
J Allergy Clin Immunol Pract; 2017; 5(3):816-818. PubMed ID: 27765459
[No Abstract] [Full Text] [Related]
9. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.
Gomez R; Harter P; Lück HJ; Traut A; Kommoss S; Kandel M; du Bois A
Int J Gynecol Cancer; 2009 Oct; 19(7):1284-7. PubMed ID: 19823066
[TBL] [Abstract][Full Text] [Related]
10. Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization.
Rose PG; Metz C; Link N
Int J Gynecol Cancer; 2014 Nov; 24(9):1603-6. PubMed ID: 25304679
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin desensitization.
Choi J; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):137-41. PubMed ID: 15328672
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy.
Shibata N; Kawakami K; Hisanori S; Kobayashi K; Yunokawa M; Kanao H; Taki I; Murase R; Kamei D; Yamaguchi M
Anticancer Res; 2022 Feb; 42(2):1091-1097. PubMed ID: 35093911
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin hypersensitivity reactions.
Winkeljohn D; Polovich M
Clin J Oncol Nurs; 2006 Oct; 10(5):595-8. PubMed ID: 17063613
[TBL] [Abstract][Full Text] [Related]
15. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
16. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
18. Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions.
Lax T; Long A; Banerji A
J Allergy Clin Immunol Pract; 2015; 3(6):856-62. PubMed ID: 26432514
[TBL] [Abstract][Full Text] [Related]
19. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Moon DH; Lee JM; Noonan AM; Annunziata CM; Minasian L; Houston N; Hays JL; Kohn EC
Br J Cancer; 2013 Aug; 109(4):1072-8. PubMed ID: 23867999
[TBL] [Abstract][Full Text] [Related]
20. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R
Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
